Rare diseases
Investigational molecules
Locations
Recruiting trials first
1 clinical trial in this condition
Study on Belapectin for Preventing Esophageal Varices in Patients with NASH Cirrhosis
BelgiumIn short
Esophageal varices are enlarged, swollen veins in the lower part of the esophagus that can rupture and cause life-threatening bleeding. These abnormal blood vessels typically develop when blood flow to the liver is blocked or slowed, most commonly due to liver disease. Understanding when and how to diagnose these varices is crucial, as early detection can prevent dangerous bleeding episodes and save lives.
Diagnosing esophageal varices requires careful attention to who should be tested and when. Not everyone needs screening for these enlarged veins, but certain groups of people face higher risks and should undergo regular evaluation. The timing of diagnosis can make a significant difference in preventing serious complications.
People who have been diagnosed with cirrhosis, which is severe scarring of the liver, should have diagnostic testing for esophageal varices. At the time of cirrhosis diagnosis, about 30 percent of people already have enlarged veins in their esophagus. This number increases dramatically over time—up to 90 percent will develop varices within the next ten years after their cirrhosis diagnosis.
Anyone with signs of liver disease should discuss screening with their doctor. These signs include yellowing of the skin and eyes (called jaundice), fluid buildup in the abdomen known as ascites, swelling in the legs and feet, unexplained itching without a visible rash, or confusion and disorientation. These symptoms suggest that the liver is not working properly, which increases the chance that blood vessels in the esophagus have become enlarged.
People should seek immediate medical attention if they experience symptoms that suggest active bleeding. Vomiting blood, whether it looks like coffee grounds or appears bright red, requires emergency care. Similarly, black tarry stools or bright red blood in the stool indicates bleeding somewhere in the digestive system. Other warning signs include feeling extremely tired, weak, or lightheaded, which may mean blood loss is occurring. These are not situations where someone should wait—calling emergency services or going to the hospital right away is essential.
Healthcare professionals may also recommend screening for people who have chronic liver diseases even before cirrhosis develops, particularly if there are other risk factors present. Conditions like chronic hepatitis B or C infection, long-term heavy alcohol use, or nonalcoholic fatty liver disease can all lead to liver damage over time. Regular monitoring allows doctors to detect varices before they become dangerous.
Diagnosing esophageal varices involves several different approaches. The most reliable and preferred method is an examination that allows doctors to directly see inside the esophagus. Additional tests can provide supporting information about the condition of the liver and blood vessels, helping to paint a complete picture of what is happening inside the body.
Upper endoscopy, also called esophagogastroduodenoscopy or EGD, is the most important diagnostic tool for identifying esophageal varices. During this procedure, a doctor inserts a long, thin, flexible tube called an endoscope through the mouth and down into the esophagus. At the tip of this tube is a tiny camera that sends images to a monitor, allowing the medical team to examine the esophagus, stomach, and the beginning of the small intestine.
What makes upper endoscopy so valuable is that it allows doctors to see the varices directly. They can measure how large the enlarged veins are, which is important because size predicts the risk of bleeding. Small varices have about a 5 percent yearly risk of bleeding for the first time, while large varices carry a 15 percent yearly risk. Doctors also look for specific warning signs during the examination, such as red streaks or red spots on the varices, which indicate a higher chance that bleeding will occur soon.
The endoscopy procedure also allows treatment to be performed at the same time if necessary. If doctors find large varices or signs that bleeding is likely, they can immediately place rubber bands around the swollen veins or inject medication to help prevent future bleeding. This dual purpose—diagnosis and treatment in one session—makes endoscopy especially useful.
Before any testing with equipment, doctors begin with a thorough physical examination and review of the patient's medical history. During the physical exam, healthcare providers look for signs that suggest liver disease or portal hypertension, which is high blood pressure in the vein that carries blood to the liver. They check the skin and eyes for yellowing, examine the abdomen for swelling or tenderness, and look at the legs and feet for fluid accumulation.
Understanding a person's medical background helps doctors assess risk. Questions about alcohol use, previous hepatitis infections, family history of liver disease, and current medications all provide clues. If someone already has a diagnosis of cirrhosis or chronic liver disease, this immediately signals the need for screening even if no symptoms are present. The physical exam and history guide decisions about which diagnostic tests to order.
While upper endoscopy remains the preferred method, certain imaging tests can suggest the presence of esophageal varices or help evaluate related problems. Abdominal CT scans, which use X-rays to create detailed cross-sectional images of the body, can sometimes show enlarged veins in the esophagus. Similarly, Doppler ultrasound of the splenic and portal veins can indicate problems with blood flow that lead to varices.
A special type of ultrasound called transient elastography measures how stiff or scarred the liver tissue has become. This test helps determine if someone has portal hypertension, which is the underlying problem that causes varices to form. While these imaging methods cannot replace endoscopy for definitively diagnosing esophageal varices, they provide valuable information about the overall health of the liver and blood vessels.
Blood tests do not directly show esophageal varices, but they help doctors understand how well the liver is functioning and whether complications might be developing. When someone comes to the hospital with signs of bleeding, doctors check blood pressure, heart rate, and perform a rectal examination to look for blood in the stool. Blood tests measure how much blood has been lost and check for signs of liver damage or poor liver function.
If massive bleeding is suspected, a tube may be inserted through the nose into the stomach to look directly for signs of active bleeding. This helps medical teams determine how urgent the situation is and what treatment is needed immediately. These tests work together with other diagnostic methods to give a complete understanding of the patient's condition.
Because esophageal varices are so common in people with cirrhosis, regular screening is recommended even when no symptoms are present. When someone is first diagnosed with cirrhosis, doctors typically perform an upper endoscopy to check for varices. If no varices are found during that first examination, follow-up endoscopies are usually scheduled every two to three years to watch for changes.
If small varices are discovered, more frequent monitoring is needed. Doctors often recommend repeat endoscopy every one to two years to see if the varices are getting larger. People at highest risk of rapid variceal growth—including those with alcoholic cirrhosis, more severe liver impairment, or those who have specific warning signs visible during endoscopy—should have even shorter intervals between examinations. This regular surveillance allows treatment to begin before dangerous bleeding occurs.
Clinical trials investigating new treatments for esophageal varices or related liver conditions require specific diagnostic criteria to determine which patients can participate. These trials use standardized testing methods to ensure that participants truly have the condition being studied and to measure whether treatments are working effectively.
Upper endoscopy is almost always required as part of clinical trial screening. Researchers need clear documentation of the presence and size of varices, often using standardized grading systems to classify them as small, medium, or large. The endoscopy must be performed within a certain time frame before enrollment—typically within a few weeks or months—to ensure that the findings are current and accurate.
Many clinical trials also require measurement of portal pressure, although this test is not routinely done outside of research settings. The measurement involves inserting a thin tube through a vein in the groin or neck and advancing it to the liver to directly measure blood pressure in the portal vein system. This measurement, called the hepatic vein pressure gradient or HVPG, provides precise information about how severe the portal hypertension is. A gradient greater than 5 millimeters of mercury indicates portal hypertension, while values above 10 millimeters of mercury indicate clinically significant disease that can cause varices to bleed.
Laboratory tests documenting liver function are standard requirements for clinical trial entry. These typically include measurements of liver enzymes, bilirubin levels, blood clotting function, and kidney function. Trials often use scoring systems like the Child-Pugh classification, which grades the severity of cirrhosis based on laboratory values and physical findings. Only patients within certain score ranges may be eligible for particular studies.
Imaging studies beyond endoscopy may be required to fully characterize the liver disease. Abdominal ultrasound or CT scans help rule out liver cancer or other complications that might affect trial eligibility. Some studies require transient elastography to objectively measure liver stiffness. All of these tests together help researchers select appropriate participants and establish baseline measurements against which treatment effects can be compared.
Documentation of any previous episodes of variceal bleeding is another common requirement. Trials may specifically seek patients who have never bled before (for primary prevention studies) or those who have experienced bleeding in the past (for secondary prevention studies). Detailed medical records, including reports from previous endoscopies and hospitalizations, must be provided to verify the patient's bleeding history.
The outlook for people with esophageal varices depends heavily on whether bleeding occurs and how severe the underlying liver disease has become. The most critical factor affecting prognosis is the severity of cirrhosis—more advanced liver disease leads to larger varices that are more likely to rupture. People with decompensated cirrhosis, meaning the liver is no longer able to perform its essential functions adequately, face greater risks than those with earlier-stage disease.
For people who have varices but have never experienced bleeding, the risk increases with the size of the veins. Small varices carry approximately a 5 percent chance of first-time bleeding within a year, while large varices have about a 15 percent yearly risk. Certain features visible during endoscopy, such as red streaks or spots on the varices, indicate higher risk. The presence of these warning signs, combined with severe liver disease, creates the highest danger of bleeding episodes.
Once bleeding from esophageal varices occurs, the situation becomes more serious. Without treatment, bleeding typically does not stop on its own and can quickly become life-threatening. Even with modern medical treatment, bleeding often returns after the first episode—about 50 percent of people who bleed once will experience another bleeding episode within the first one to two years if preventive treatment is not provided. Treatment with medications, endoscopic procedures, or both can significantly reduce this risk of recurrent bleeding.
The overall prognosis depends greatly on the health of the liver and whether the underlying liver disease can be treated or controlled. People who stop drinking alcohol if they have alcoholic liver disease, who receive effective treatment for hepatitis infections, or who successfully manage other causes of liver damage may see improvement in their liver function over time. In contrast, continued damage to the liver worsens portal hypertension and increases both the size of varices and the risk of dangerous bleeding.
Bleeding from esophageal varices carries a serious mortality risk. When a bleeding episode occurs, approximately 20 percent of patients die within the first six weeks, even with treatment. This statistic underscores why prevention of first-time bleeding and prevention of recurrent bleeding after an initial episode are such important goals of medical care.
Variceal bleeding is the most common cause of hospitalization and death in people with cirrhosis. Among all the serious complications that can arise from advanced liver disease, bleeding varices pose the greatest immediate threat to life. The survival rate depends on multiple factors including how quickly bleeding is controlled, the amount of blood lost, the presence of other medical problems, and the overall condition of the liver.
Long-term survival is closely tied to the progression of liver disease. For people with cirrhosis who develop esophageal varices, the severity of the cirrhosis itself—not just the varices—determines much of the overall prognosis. Those with well-compensated cirrhosis who receive appropriate preventive treatment for their varices can live for many years. However, as cirrhosis advances and the liver loses more function, survival rates decline regardless of whether bleeding occurs.
People who have advanced liver disease and experience variceal bleeding may be considered for liver transplantation, which can dramatically improve survival. For those who are not candidates for transplant or who continue to have bleeding despite treatment, the outlook remains challenging. Bleeding esophageal varices in the context of severe liver disease represents a poor prognosis overall.
This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
